Adaptive Biotechnologies Corporation (ADPT) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A section reveal several positive aspects: raised revenue guidance, improved margins, and strong growth in MRD volumes. The company's strategic partnerships and regulatory advancements, along with a clear path to profitability, are positive indicators. Despite some vague management responses, the overall sentiment is optimistic. The stock is likely to see a positive movement, with increased MRD revenue and improved cash burn guidance contributing to investor confidence.
Key Financial Performance
Adjusted EBITDA $7 million, reflecting strong sequential growth. This is a significant improvement compared to a deficit of $6.1 million a year ago, driven by strong execution and scalability of the MRD business.
MRD Revenue $56.8 million, a 52% year-over-year increase. This growth was driven by robust increases in clinical volume and ASP.
clonoSEQ Clinical Revenue 83% year-over-year growth and 18% quarter-over-quarter growth. This was due to broad-based volume expansion across all reimbursed indications and increased ASP.
clonoSEQ Test Volume 27,111 tests delivered, a 38% year-over-year increase. This growth was attributed to strategic priorities such as blood-based testing and community-based testing.
U.S. clonoSEQ ASP Over $1,340 per test, a 28% year-over-year increase. This reflects continued strength in cash collections and improved pricing through contracting initiatives.
Sequencing Gross Margin 66%, a 10 percentage point improvement year-over-year. This was driven by cost efficiencies from the NovaSeq X implementation and higher volumes.
Total Company Revenue $94 million, representing a 102% year-over-year increase. This includes $33.7 million of noncash revenue from Genentech.
Net Income $9.5 million for the quarter, reflecting improved profitability.
Cash Position $217 million at the end of the quarter, supported by a 51% reduction in cash burn through the first 9 months of the year compared to last year.
MRD Pharma Revenue 11% year-over-year growth, including $6.5 million in milestone revenue. This was driven by strong partner demand and sustained program activity.
Immune Medicine Revenue $3.4 million, down from $5.5 million a year ago, reflecting a decline in pharma and academic services revenue.
Total Operating Expenses $83.7 million, up 6% year-over-year but flat sequentially. The increase was primarily due to higher SG&A expenses and cost of revenue from volume growth, partially offset by lower R&D expenses.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
clonoSEQ: Achieved significant growth with clinical revenue up 83% year-over-year and 18% quarter-over-quarter. Delivered over 27,100 tests, a 38% increase year-over-year. U.S. ASP increased to over $1,340 per test. Expanded reimbursement footprint with new payer contracts and achieved policy wins in DLBCL and CLL.
T-cell depletion antibody program: Selected lead antibody candidate for autoimmune indication. Progressed towards IND-enabling studies with robust preclinical data.
MRD business: Revenue grew 52% year-over-year to $56.8 million. Achieved cash flow positivity and adjusted EBITDA of $7 million. Expanded clinical utility and integration into patient care. Increased test volume and ASP, with a long-term ASP target of $1,700-$1,800 per test.
Immune Medicine: Revenue from pharma and academic services was $3.4 million. Concluded partnership with Genentech, releasing exclusivity and opening new partnership opportunities.
Operational efficiencies: Implemented NovaSeq X Plus, improving sequencing gross margin by 10 percentage points year-over-year to 66%. Reduced cash burn by 51% year-over-year, ending the quarter with $217 million in cash.
EMR integrations: Completed 11 integrations, driving volume growth and deeper account retention. Integrated accounts contributed nearly 40% of commercial tests.
Strategic shifts: Concluded Genentech partnership, accelerating data generation and AI/ML modeling capabilities. Focused on high-value partnership opportunities and advancing T-cell depletion antibody program.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Uncertainty: The FDA's current case-by-case acceptance of MRD as an endpoint in lymphoid cancers introduces uncertainty in gaining broader regulatory acceptance for accelerated approvals.
Partnership Termination: The conclusion of the partnership with Genentech due to their internal portfolio prioritization could impact Adaptive's ability to leverage prior collaborations for growth.
Revenue Dependency: A significant portion of MRD revenue is tied to milestone payments and specific indications like multi myeloma, which could pose risks if these revenue streams decline.
Competitive Pressures: The need to build a scalable moat around clonoSEQ to protect against new entrants highlights competitive risks in the MRD market.
Operational Costs: While operating expenses remained stable, the company still faces challenges in maintaining cost efficiencies as it scales its operations.
Economic Uncertainty: Broader economic conditions could impact payer contracts, reimbursement rates, and overall test volume growth.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
MRD Revenue Guidance: The company has raised its full-year MRD revenue guidance to a range of $202 million to $207 million, up from the prior range of $190 million to $200 million. This reflects stronger-than-expected clinical revenue performance in Q3 and higher MRD milestone revenue for the year.
Test Volume Expectations: The company expects to deliver approximately 104,000 tests for the year, exceeding the prior growth target of 35% over 2024.
MRD Milestone Revenue: The company anticipates MRD milestone revenue between $18 million and $19 million, up from the previous $14 million to $15 million range.
MRD Revenue Growth: The outlook implies 39% to 42% total MRD revenue growth year-over-year and 38% to 42% growth for the MRD base business, excluding milestones at the midpoint.
Operating Expense Guidance: The company is tightening and lowering the top end of its total company operating expense guidance, including cost of revenue, to $335 million to $340 million from the previous range of $335 million to $345 million.
Cash Burn Guidance: The company is narrowing and lowering its full-year company cash burn guidance to $45 million to $50 million from the prior $45 million to $55 million range, driven primarily by higher MRD revenue.
Immune Medicine Cash Burn: The company continues to expect $25 million to $30 million cash burn from Immune Medicine.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide insights on the $200 million backlog in the MRD pharma business and its release over the next several quarters?
A:The backlog is expected to be recognized over a 5 to 7-year timeframe. The company anticipates continuing growth in a similar range to this year, supported by strong pipeline developments in multiple myeloma, NHL, and leukemia. New bookings have been strong, and MRD is expected to play a role as an endpoint in additional indications.
Q:Is a 30% MRD volume growth achievable in 2026 given the current drivers?
A:Management did not provide specific guidance for 2026 but expressed confidence in the business trajectory due to factors like Epic integrations, blood testing, and community penetration.
Q:What is the outlook for clonoSEQ ASPs next year and beyond?
A:While no firm number was provided for 2026, the company is confident about meaningful ASP growth, supported by a strong foundation and momentum around coverage. The long-term target remains $1,700 to $1,800.
Q:What are the growth trends in mature EMR integrations and their impact on accounts?
A:Mature integrated accounts continue to grow faster than non-integrated ones, with a 9% quarter-over-quarter growth in Q3 compared to 6% for non-integrated accounts. Integration benefits include democratized ordering, reduced HCP workload, and strengthened competitive moats.
Q:What kind of tests compete with clonoSEQ, and how does the company view its competitive position?
A:In many indications, the main competition is the lack of testing or traditional methods. Emerging competition exists in diffuse large B-cell lymphoma (DLBCL), but the company is confident in its market-leading position due to clinical experience, Medicare coverage, and universal testing capabilities.
Q:Have recent guideline updates impacted utilization and commercial conversations?
A:Guideline updates in multiple myeloma, DLBCL, and CLL have started to impact utilization and strengthen commercial conversations. For example, in multiple myeloma, guidelines support the value of ID tests at diagnosis, and in CLL, they specify testing frequency, aiding community doctor adoption.
Q:What tools in the EMR are being used to increase testing frequency and utilization?
A:Tools like treatment plans, order sets, and analytics within Epic are being used to schedule and facilitate testing. For example, clinicians can set up specific actions for patient testing, and staff can track patients due for tests, which helps optimize testing frequency.
Q:What is the current penetration in the community setting, and are there plans to expand the sales force?
A:Community penetration is at 30%, with significant growth potential. The company is focusing on integrations like OncoEMR and does not plan significant sales force expansion, maintaining 65 reps with half focused on the community setting.
Q:What drove the improvement in sequencing gross margins, and what is the outlook?
A:Sequencing gross margin improved to 66%, driven by the NovaSeq X transition, which contributed 2 percentage points. The company expects continued improvement, reaffirming a 5 to 8 percentage point increase post-launch.
Q:What is the status of blood-based testing and its contribution to MRD tests?
A:Blood-based testing now accounts for 45% of MRD tests, achieving the year-end goal early. Increases are seen in both traditionally marrow-based tests like ALL and multiple myeloma, as well as primarily blood-based indications like DLBCL and CLL.
Q:What is the progress in DLBCL and its future potential?
A:DLBCL now contributes 9% of MRD volume, up from 6% a year ago, and is poised to overtake CLL as the third-largest indication. Increased data generation and pharma interest in MRD-guided treatment are driving growth.
Q:What are the company's plans for investments and balancing growth with profitability?
A:The company plans to continue investing in blood-based testing, clinical studies, and data generation while maintaining control over OpEx. It aims to balance growth with achieving cash flow positivity.
Q:Is there seasonality in Q4 MRD numbers, and how does it affect guidance?
A:Yes, Q4 typically experiences seasonality due to holidays, which is factored into the guidance. Despite this, the company expects strong long-term growth.
Q:What is the timeline for clonoSEQ to become a primary endpoint in indications beyond multiple myeloma?
A:Efforts are ongoing for CLL and DLBCL to establish MRD as an accelerated endpoint for approval. While it took 10 years for multiple myeloma, advancements are expected to be faster for other indications due to existing blueprints and data collection.
Q:Review of Unclear Management Responses
A:Management avoided providing specific guidance for 2026 MRD volume growth and clonoSEQ ASPs, using vague language like 'confidence in the trajectory' and 'meaningful growth.' They also did not quantify the lift from EMR tools or provide a clear timeline for clonoSEQ becoming a primary endpoint in other indications.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ASP policy
ASP strength
ASP utility
Adaptive exclusivity
Biotechnologies Conference
CHMP vote
CLL MRD
CLL backlog
CLL booking
CLL life
CLL volume
CMC tox
Chad result
FDA MRD
Flatiron account
Immune Medicine
MRD Immune
MRD cash
MRD increase
application
base
care
cash collection
cash flow
clonoSEQ volume
deficit
direction
efficiency
footprint
model
multi myeloma
noncash
portfolio
position
priority
profitability
summary
testing clonoSEQ
track
treatment
win
ADPT Transcript
Adaptive Biotechnologies Corporation (ADPT) Q1 2026 Earnings Call Transcript
Positive5-5
The earnings call reflects strong revenue growth driven by MRD, improved EBITDA in the MRD segment, and optimistic guidance with margin expansion and increased pharma partnerships. Despite some concerns about expenses and ongoing investments, the market strategy and business updates are robust. The Q&A highlights progress in community account engagement, reimbursement profiles, and EHR integration, with positive analyst sentiment. While some uncertainties remain, particularly around Medicare bundle increases and contract transitions, the overall sentiment is positive, anticipating a 2-8% stock price increase.
Adaptive Biotechnologies Corporation (ADPT) Q4 2025 Earnings Call Transcript
Positive2-6
The company reported strong financial performance with significant revenue growth, improved margins, and a substantial reduction in cash burn. Raised revenue guidance and a positive EBITDA outlook further bolster confidence. Despite some conservative growth assumptions and lack of specific contract details, the overall sentiment is positive, supported by strong MRD performance and strategic partnerships like Pfizer.
Adaptive Biotechnologies Corporation (ADPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-12
Adaptive Biotechnologies Corporation (ADPT) Q3 2025 Earnings Call Transcript
Positive11-6
The earnings call summary and Q&A section reveal several positive aspects: raised revenue guidance, improved margins, and strong growth in MRD volumes. The company's strategic partnerships and regulatory advancements, along with a clear path to profitability, are positive indicators. Despite some vague management responses, the overall sentiment is optimistic. The stock is likely to see a positive movement, with increased MRD revenue and improved cash burn guidance contributing to investor confidence.
ADPT Slides
ADPT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
